Creative Medical Technology Holdings Inc (CELZ) - Total Assets
Based on the latest financial reports, Creative Medical Technology Holdings Inc (CELZ) holds total assets worth $6.44 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore CELZ cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Creative Medical Technology Holdings Inc - Total Assets Trend (2006–2025)
This chart illustrates how Creative Medical Technology Holdings Inc's total assets have evolved over time, based on quarterly financial data. See Creative Medical Technology Holdings Inc (CELZ) shareholders funds for net asset value and shareholders' equity analysis.
Creative Medical Technology Holdings Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Creative Medical Technology Holdings Inc's total assets of $6.44 Million consist of 94.7% current assets and 5.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 92.3% |
| Accounts Receivable | $52.08K | 0.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $407.23K | 5.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how Creative Medical Technology Holdings Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Creative Medical Technology Holdings Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Creative Medical Technology Holdings Inc's current assets represent 94.7% of total assets in 2025, a decrease from 100.0% in 2006.
- Cash Position: Cash and equivalents constituted 92.3% of total assets in 2025, up from 0.0% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 0.0% in 2006.
- Asset Diversification: The largest asset category is intangible assets at 5.2% of total assets.
Creative Medical Technology Holdings Inc Competitors by Total Assets
Key competitors of Creative Medical Technology Holdings Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
Creative Medical Technology Holdings Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 19.69 | 27.39 | 0.11 |
| Quick Ratio | 19.69 | 27.39 | 0.11 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.75 Million | $7.56 Million | $-1.29 Million |
Creative Medical Technology Holdings Inc - Advanced Valuation Insights
This section examines the relationship between Creative Medical Technology Holdings Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.14 |
| Latest Market Cap to Assets Ratio | 0.31 |
| Asset Growth Rate (YoY) | 17.1% |
| Total Assets | $7.81 Million |
| Market Capitalization | $2.45 Million USD |
Valuation Analysis
Below Book Valuation: The market values Creative Medical Technology Holdings Inc's assets below their book value (0.31x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Creative Medical Technology Holdings Inc's assets grew by 17.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Creative Medical Technology Holdings Inc (2006–2025)
The table below shows the annual total assets of Creative Medical Technology Holdings Inc from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $7.81 Million | +17.10% |
| 2024-12-31 | $6.67 Million | -37.76% |
| 2023-12-31 | $10.72 Million | -44.15% |
| 2022-12-31 | $19.19 Million | +70.27% |
| 2021-12-31 | $11.27 Million | +1469.88% |
| 2020-12-31 | $717.77K | +35.22% |
| 2019-12-31 | $530.80K | +11.24% |
| 2018-12-31 | $477.16K | +134.88% |
| 2017-12-31 | $203.15K | -37.01% |
| 2016-12-31 | $322.51K | +149211.11% |
| 2015-12-31 | $216.00 | -77.36% |
| 2014-12-31 | $954.00 | +155.08% |
| 2013-12-31 | $374.00 | -76.15% |
| 2012-12-31 | $1.57K | -49.50% |
| 2011-12-31 | $3.10K | +650.00% |
| 2010-12-31 | $414.00 | -86.54% |
| 2009-12-31 | $3.08K | +104.73% |
| 2008-12-31 | $1.50K | -95.78% |
| 2007-12-31 | $35.63K | +21.45% |
| 2006-12-31 | $29.34K | -- |
About Creative Medical Technology Holdings Inc
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DD… Read more